Pfizer Inc.
corporate_fare Company Profile
Pfizer Inc. (NYSE:PFE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 67 items for PFE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for PFE spans 8-K, 10-Q.
Recent high-impact activity:
- Pfizer Pays $330M Upfront for Starna's In Vivo CAR-T Autoimmune Pipeline
- Padcev-Imfinzi Cuts Bladder Cancer Death Risk 42%; Blackstone Backs Obesity Drug With $1.5B
- FDA Clears Durvalumab-Enfortumab Combo for Muscle Invasive Bladder Cancer
- Blackstone to Fund Up to $1.5B of Pfizer's Monthly GLP-1 Obesity Drug Through 2028
- Pfizer Beats on Q3, Raises 2026 Revenue Guidance to $62-64B and EPS to $2.95-$3.05
Financial Snapshot
Short Interest & Short Volume
4.58 days to coverFINRA reported short interest of 134,422,620 shares in PFE as of the October 30, 2026 settlement, a 2.5% decrease from the prior period — about 4.6 days to cover at its recent average daily volume. On November 20, 2026, 34.1% of PFE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.